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Abstract
Positively charged pyridiniums are unique inhibitors to probe the structural and functional properties of the ubiquinone
reduction site of bovine heart mitochondrial complex I. In this study, we synthesized a series of neutral as well as pyridinium
analogues of MP-24 (N-methyl-4-[2-methyl-2-(p-tert-butylbenzyl)propyl]pyridinium), a selective inhibitor of one of the two
proposed binding sites of these pyridinium-type inhibitors of complex I (H. Miyoshi et al., J. Biol. Chem. 273 (1998) 17368^
17374), to elucidate the origin of its selectivity. Inhibitory potencies of all neutral and pyridinium analogues with
tetraphenylboron (TPB3), which forms an ion-pair with pyridiniums, were comparable, although the degrees of selective
inhibition by pyridiniums without TPB3 were entirely different. In contrast to MP-24, the dose^response curves of
nonselective pyridiniums and all neutral analogues were not affected by incubation conditions. These results strongly
suggested that the process of the inhibitor passage to the binding sites is responsible for the selective inhibition. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitochondrial NADH^ubiquinone oxidoreductase
(complex I) is a large enzyme that catalyzes the ox-
idation of NADH by ubiquinone coupled to proton
translocation across the inner membrane [1,2]. There
are a variety of inhibitors of mitochondrial complex
I, and with the exception of a few which inhibit elec-
tron input into the enzyme [3,4] all inhibitors act at
or close to the ubiquinone reduction site [5,6].
Among the inhibitors, positively charged neurotoxic
N-methyl-4-phenylpyridinium (MPP) and its alkyl
analogues exhibit unique inhibitory behavior with
bovine heart mitochondrial complex I [7]. Singer
and colleagues [7^11] suggested that MPP ana-
logues are bound at two sites in the enzyme, one
accessible to relatively hydrophilic inhibitors (termed
the ‘hydrophilic site’) and one shielded by a hydro-
phobic barrier on the enzyme (the ‘hydrophobic
site’), and that occupation of both sites is required
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biphasic nature of the dose^response curve, wherein I75 and I25
are the molar concentrations which give 75% and 25% inhibition
of the enzyme activity, respectively, without TPB3 ; I50 (+TPB3),
a molar concentration to give 50% inhibition in the presence of
2 WM TPB3 ; I50 (3TPB3), a molar concentration to give 50%
inhibition in the absence of TPB3 ; MPP, N-methyl-4-phenyl-
pyridinium; Q1, ubiquinone-1; SMP, submitochondrial particles ;
TPB3, tetraphenylboron
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for complete inhibition. This should be helpful in
elucidating the terminal electron transfer step in
complex I and seems to be consistent with the exist-
ence of two EPR-detectable species of complex
I-associated ubisemiquinones [12,13]. However, re-
cent radioligand binding assays suggested that ordi-
nary complex I inhibitors share a common large
binding domain in complex I [6].
We previously synthesized a series of MPP ana-
logues which are much more potent than the original
MPP and demonstrated that the presence of hydro-
phobic counter-anion tetraphenylboron (TPB3) po-
tentiates the inhibition by MPP analogues di¡er-
ently depending upon the molar ratio of TPB3 to
the inhibitors [14]. In the presence of a catalytic
amount of TPB3, the inhibitory potency of MPP
analogues was markedly enhanced, and the extent of
inhibition was almost complete. The presence of an
excess amount of TPB3 partially reactivated the en-
zyme activity, and the inhibition was partly saturated
(V50%). This complicated inhibitory behavior could
be explained by the dual binding sites model [7],
which supposes quite di¡erent hydrophobic natures
of the two sites and/or their environments.
If there are two distinct binding sites of MPP
analogues in bovine complex I, there should be spe-
ci¢c inhibitors which act selectively at one of the two
proposed binding sites since it is unlikely that the
structural properties of the two sites are completely
identical. We recently synthesized MP-24 (N-methyl-
4-[2-methyl-2-(p-tert-butylbenzyl)propyl]pyridinium),
Fig. 1) [15]. This inhibitor showed a remarkably bi-
phasic dose^response curve for the inhibition of
NADH^Q1 oxidoreductase activity in the absence
of TPB3, making this compound the ¢rst selective
inhibitor of the two sites [15]. On the basis of the
observation that even slight structural modi¢cation
of MP-24 markedly a¡ected the extent of the bipha-
sic nature of the dose^response curve, we suggested
that the selective inhibition by MP-24 is closely re-
lated to its structural speci¢city [15].
For use of MP-24 as a probe to examine the mech-
anism of the terminal electron transfer step of com-
plex I and develop further selective inhibitors, several
points concerning the mechanism of its inhibitory
e¡ect remain to be elucidated; particularly the origin
of the selective inhibition. For this purpose, neutral
analogues of MP-24 would be helpful since the e¡ect
of a positive charge on the inhibitor passage to the
binding sites can be negligible. In the present study,
we investigated the origin of the selective inhibition
of MP-24 by comparing its inhibitory e¡ects with
those of newly synthesized neutral as well as pyridi-
nium analogues of MP-24.
2. Materials and methods
2.1. Materials
MP-6, MP-17, MP-24, MP-25 and MP-26 were
synthesized according to the previously described
methods [14,15]. PMP-6, PMP-17, PMP-24, PMP-
25 and PMP-26 were the precursors of the corre-
sponding N-methyl pyridiniums. MP-29 was pre-
pared by N-ethylation of PMP-24 with ethyl tri£uo-
romethanesulfonate in dry CH2Cl2. THMP-24 and
THMP-29 were prepared by reduction of MP-24
and MP-29, respectively, with NaBH4 in ethanol
[16]. The structures of these compounds were char-
acterized by 1H NMR (Bruker AC-300) and elemen-
tal analyses for carbon, hydrogen and nitrogen, with-
in an error of þ 0.3%. Bullatacin was generously
provided by Dr. J.L. McLaughlin (Purdue Univer-
sity). Other chemicals were commercial products of
analytical grade.
2.2. Methods
Bovine heart submitochondrial particles (SMP)
were prepared by the method of Matsuno-Yagi and
Hate¢ [17] and stored in a bu¡er containing 0.25 M
sucrose and 10 mM Tris/HCl (pH 7.4) at 378‡C.
NADH^Q1 oxidoreductase activity was measured
as the rate of NADH oxidation with a Shimadzu
UV-3000 at 340 nm (O= 6.2 mM31 cm31). The reac-
tion medium contained 50 mM potassium phosphate
(pH 7.4), 0.25 M sucrose, 1 mM MgCl2, 2 mM
KCN, 0.2 WM antimycin A and the ¢nal mitochon-
drial protein concentration was 30 Wg/ml. Unless oth-
erwise noted, the reaction was started by adding
50 WM NADH after incubation of SMP with inhib-
itor for 4 min at 30‡C. Q1 was used as an electron
acceptor since this substrate yields high reaction rate
with linear kinetics [18]. The experimental conditions
for investigation of the e¡ects of incubation temper-
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ature or incubation period on the inhibition are de-
scribed in the ¢gure legends.
3. Results and discussion
MP-24 showed a marked biphasic dose^response
curve for inhibition of NADH^Q1 oxidoreductase
activity (Fig. 2), making this compound the ¢rst se-
lective inhibitor of the two sites [15]. The selectivity
of MP-24 in terms of the I75/I25 ratio was s 690
(Table 1). The complete inhibition by MP-24 without
TPB3 could not be determined because of solubility
limit above V400 WM. Such a marked biphasic na-
ture of the dose^response curve has not been re-
ported previously for complex I inhibitors. However,
complete inhibition was readily achieved at low con-
centrations of MP-24 (6 10 WM) in the presence of
2 WM TPB3 (Fig. 2). As TPB3 increases pyridinium
concentration in the membrane lipid phase due to
ion-pair formation and facilitates pyridinium passage
through the hydrophobic barrier to the binding site,
the site that is readily blocked by low concentrations
of MP-24 without TPB3 would be the hydrophilic
binding site [7,14,15].
The previous observation that the two components
of total enzyme activity exhibiting di¡erent sensitiv-
ities to MP-24 (without TPB3) showed markedly dif-
ferent pH dependencies (Fig. 7 in [15]) suggested that
MP-24 interacts with the two distinct binding sites in
complex I. To verify this and also to con¢rm whether
the apparent partial saturation of the inhibition by
MP-24 is indeed due to that of occupation of the
binding site (probably the hydrophilic site), we exam-
ined double inhibitor titrations in combination of
MP-24 and bullatacin (rolliniastatin-2), the most po-
tent inhibitor of the ubiquinone reduction site of
bovine heart mitochondrial complex I [6,19,20]. The
titration curve of bullatacin alone was linear when
exogenous ubiquinone (Q1) was used as an electron
Fig. 1. Structures of pyridinium-type inhibitors and their neu-
tral analogues synthesized in this study.
Fig. 2. Inhibition of NADH^Q1 oxidoreductase activity by MP-
24 and MP-29. The reaction medium contained 50 mM potassi-
um phosphate (pH 7.4), 0.25 M sucrose, 1 mM MgCl2, 2 mM
KCN, 0.4 WM antimycin A, and a ¢nal mitochondrial protein
concentration of 30 Wg/ml. The reaction was started by adding
50 WM NADH after incubation of SMP with the indicated con-
centrations of inhibitors for 4 min at 30‡C. The e¡ects of MP-
24 and MP-29 in the absence of TPB3 are shown by closed
circles and squares, respectively. The e¡ect of MP-24 in the
presence of 2 WM TPB3 is also shown (open circles). The con-
trol enzyme activity was 0.62 Wmol NADH oxidized per min/
mg of protein. The extent of inhibition by 0.1 WM piericidin A
was taken as 100%.
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acceptor, and complete inhibition was attained at
about 1.8 nM (Fig. 3, see also [20]). In the presence
of 10 or 100 WM MP-24 which elicited 50V60% in-
hibition, complete inhibition by bullatacin was
achieved at around 0.9 nM irrespective of MP-24
concentration. As a reference, titration by bullatacin
was carried out in combination with diphenyleneio-
donium (DPI), which inhibits electron input into the
enzyme [4]. In the presence of 2.5 WM DPI which
elicits about 50% inhibition, complete inhibition by
bullatacin was attained at an identical concentration
with that obtained in the absence of DPI (i.e., about
1.8 nM). These results showed that the extent of
inhibition by MP-24 and that of occupation of the
binding sites are comparable. This result along with
the previous ¢ndings described above [15] suggested
that MP-24 interacts with two distinct binding sites
in complex I and the partial saturation of the inhi-
bition by MP-24 is due to that of occupation of the
binding site.
The extent of selective inhibition by MP-24 in
Table 1
Summary of the inhibition of complex I activity by pyridinium-type inhibitors and their neutral forms
Inhibitors I75/I25 Ia25 (WM) I50 (+TPB
3)b (WM) I50 (3TPB3)c (WM)
MP-24 s 690d 0.58 0.30 ND
MP-6 207 0.83 0.33 ND
MP-17 19 0.93 0.72 6.3
MP-25 14 2.1 2.3 9.5
MP-26 152 0.67 0.34 ND
MP-29 38 0.61 0.18 6.1
PMP-24 4.6 ^ ND 0.063
PMP-6 5.0 ^ ND 0.065
PMP-17 6.3 ^ ND 0.075
PMP-25 3.8 ^ ND 1.95
PMP-26 5.6 ^ ND 0.052
THMP-24 5.2 ^ ND 0.073
THMP-29 6.5 ^ ND 0.029
The I75/I25 ratio was used as an index of the biphasic nature of the dose^response curve, where I75 and I25 are the molar concentra-
tions which gave 75% and 25% inhibition of the control NADH^Q1 oxidoreductase activity, respectively, without TPB3. The I50
(+TPB3) and I50 (3TPB3) values, i.e., the molar concentrations which gave 50% inhibition, were obtained with and without 2 WM
TPB3, respectively. The values are averages from at least two independent measurements.
aThe I25 values (without TPB3) of pyridiniums are listed since the values can be regarded as indexes of inhibitor sensitivity of the hy-
drophilic binding site.
bND, not determined because the I50 values of the neutral analogues were identical to those obtained without TPB3.
cND, not determined since the I50 values of MP-24, MP-6 and MP-26 could not be accurately estimated due to relatively large experi-
mental error in independent experiments. This is because 50% inhibition by these compounds was observed in the plateau region of
biphasic dose^response curves.
dThe value could not be determined because this inhibitor did not elicit 75% inhibition up to the solubility limit (V400 WM). It
should be noted that the value is highly a¡ected by incubation conditions [15].
Fig. 3. Inhibition of NADH^Q1 oxidoreductase activity by bul-
latacin. The experimental conditions were the same as those de-
scribed in the legend to Fig. 2. Titration by bullatacin alone is
shown by open circles. Titration by bullatacin was performed
in the presence of 10 WM MP-24 (open squares), 100 WM MP-
24 (closed squares) or 2.5 WM DPI (closed circles).
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terms of I75/I25 ratio was markedly diminished even
by slight structural modi¢cation (Table 1). As an
example, the titration curve of MP-29 (without
TPB3), which possesses N-ethyl group in place of
N-methyl group of MP-24, is shown in Fig. 2 (closed
squares). Judging from the structural dependency of
the selective inhibition revealed using a wide variety
of pyridiniums [14,15], it is evident that hydropho-
bicity of the inhibitors is not a determining factor of
the extent of selective inhibition. Irrespective of wide
variations in I75/I25 ratio, inhibitory potencies of the
pyridiniums in the presence of 2 WM TPB3, in terms
of I50 (+TPB3), were comparable except for that of
MP-25 (Table 1)1. As TPB3 facilitates pyridinium
passage through the hydrophobic barrier to the bind-
ing sites [7,14,15], it is unlikely that a di¡erence in
the intrinsic inhibitor sensitivities between the two
binding sites is responsible for the observed selective
inhibition.
To verify this notion, we compared the inhibitory
potencies of neutral forms of the pyridiniums to ex-
clude disadvantageous e¡ects of a positive charge on
the inhibitor passage through the hydrophobic bar-
rier to the binding sites. It should be mentioned that
semiempirical molecular orbital calculation study
with AM1 parameterization showed that stable con-
formation of the neutral analogues of MP-24 (i.e.,
PMP-24 and THMP-24) is identical to that of MP-
24. The dose^response curves of the neutral ana-
logues showed no biphasic nature, as indicated by
their I75/I25 ratios (Table 1). The inhibitory potencies
of the neutral analogues in terms of the I50 (3TPB3)
values were comparable except for that of PMP-25
(Table 1) 1, although the selectivities were entirely
di¡erent among the corresponding pyridiniums. The
relatively poor structural dependency of the inhibi-
tory potencies may re£ect the large cavity-like struc-
ture of the ubiquinone reduction domain of the en-
zyme [6,21]. Moreover, although the inhibitory
potencies of the neutral analogues (I50 (3TPB3))
were greater than those of corresponding pyridi-
niums with 2 WM TPB3 (I50 (+TPB3)), structural
dependencies of the two potencies were comparable.
For instance, para-substituted derivatives (MP-24,
PMP-24) were much more potent than ortho-substi-
tuted derivatives (MP-25, PMP-25), and N-ethyl de-
rivatives (MP-29, THMP-29) were slightly more po-
tent than N-methyl derivatives (MP-24, THMP-24).
Thus, these results indicated not only that the di¡er-
ence in the intrinsic inhibitor sensitivities between the
two binding sites is not pronounced, but also that
structural speci¢city of the inhibitor sensitivities at
the binding sites is not associated with that of the
observed selective inhibition. Therefore, the possibil-
ity that a di¡erence in the intrinsic MP-24 sensitiv-
ities between the two binding sites is responsible for
the observed selective inhibition could be excluded.
On the other hand, we previously reported that
with longer incubation periods or higher incubation
temperatures of SMP with MP-24, the biphasic titra-
tion curve of this inhibitor becomes less distinct, sug-
gesting that access of MP-24 to the hydrophobic
binding site is promoted by prolongation of incuba-
tion and/or increasing incubation temperature [15].
In this sense, the selectivity of interest is highly de-
pendent on incubation conditions. Murphy et al. [11]
showed that partitioning of pyridiniums possessing
hydrophobic substituent(s) into submitochondrial
particles is established more rapidly than the devel-
opment of inhibition. On the basis of these observa-
tions, we proposed that the level of the energetic
barrier involving inhibitor passage to the binding
sites after partitioning into the membrane is respon-
sible for the observed selectivity [15].
If this is the case, the titration curves of both non-
selective pyridiniums and all the neutral analogues of
MP-24 would not vary with di¡erent incubation con-
ditions. We therefore examined the titration curves
of MP-17, MP-25, PMP-24, and THMP-24 under
various incubation periods (i.e., for 4, 10 or 30 min
at 30‡C) or temperatures (i.e., at 20‡C, 25‡C or 30‡C
for 4 min incubation). As expected, their titration
curves were not a¡ected by the incubation condi-
tions, as shown in Fig. 4 taking the e¡ect of incuba-
tion temperature on inhibition by MP-17 as an ex-
ample. Titration by MP-24 under the same
1 The activities of ortho-substituted derivatives (MP-25 and
PMP-25) were less potent than those of the corresponding para-
substituted derivatives (MP-24 and PMP-24, respectively), prob-
ably because the position of the nitrogen atom in the heterocycle
is important for interaction with the binding site. The marked
loss of inhibitory potency of [2-methyl-2-(p-tert-butylbenzyl)pro-
pyl]benzene (I50 (3TPB3), 20 WM), which possesses a benzene
ring in place of a pyridine ring of PMP-24, supported this sug-
gestion.
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experimental conditions is also shown in Fig. 4 as a
reference. Complete inhibition by MP-17 was at-
tained at less than 10 WM in the presence of 2 WM
TPB3 irrespective of incubation temperature (data
not shown). In contrast, MP-24 did not show com-
plete inhibition even with 2 WM TPB3 at 20‡C,
although complete inhibition was readily attained
at less than 10 WM at 30‡C (Fig. 2). These observa-
tions indicated that the energetic barrier preventing
access of MP-24 to the binding sites is signi¢cantly
higher than that of nonselective pyridinium MP-17.
Based on the present observations, we concluded
that the process of the inhibitor passage to the bind-
ing sites is responsible for the selective inhibition by
MP-24. Similar notion had been proposed to explain
the complicated inhibitory behavior of an original
MPP [7]. The high structural speci¢city required
for the selectivity would be closely related to the level
of the energetic barrier preventing access of the in-
hibitor to the binding sites.
The present results were discussed on the basis of
heterogeneity of the two binding sites of pyridinium-
type inhibitors, which was originally proposed by
Singer’s group [7^11]. Recently, from the radioligand
binding assay [6] and the photoa⁄nity labeling study
[24], it was claimed that ordinary complex I inhibi-
tors share a common binding domain with partially
overlapping sites, although the stoichiometry of in-
hibitor binding relative to the domain was not pre-
cisely de¢ned in the studies. If there is only one in-
hibitor binding domain in complex I, the complexity
of inhibitory action of MP-24 would have to be in-
terpreted by another scenario. For instance, two mol-
ecules of MP-24 per one large binding domain may
be required for complete inhibition of the enzyme
activity, as suggested for E-L-methoxyacrylate inhib-
itors at center P of cytochrome bc1 complex [22,23].
The binding of the ¢rst molecule of this charged in-
hibitor may induce conformational change of the
enzyme, which results in signi¢cant decrease in the
binding a⁄nity of the second inhibitor molecule to
the domain. Even in this case, the high structural
speci¢city of MP-24 including the existence of a pos-
itive charge could be closely related to this phenom-
enon.
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